Literature DB >> 29417224

Influence of dietary iron intake restriction on the development of hypertension in weanling prehypertensive rats.

Keisuke Okuno1, Yoshiro Naito2, Seiki Yasumura1, Hisashi Sawada1, Makiko Oboshi1, Koichi Nishimura1, Masanori Asakura1, Masaharu Ishihara3, Tohru Masuyama1.   

Abstract

Hypertension is a major public health problem leading to death. To reduce the morbidity and mortality in patients with hypertension, it is crucial to develop a novel strategy for prevention of hypertension. We have currently reported an attempt at dietary iron intake restriction as non-pharmacological treatment of hypertension in patients with hypertension. However, it remains fully unknown whether dietary iron restriction prevents the development of hypertension. We investigated the influence of dietary iron restriction on the development of hypertension in weanling pre-hypertensive model rats. 3-week-old male stroke-prone spontaneously hypertensive rats (SHR-SP) were randomly divided into two groups and were given an ad libitum normal diet or an iron-restricted diet for 12 weeks. Blood pressure was progressively increased in SHR-SP according to growth, while dietary iron restriction attenuated the development of hypertension. Proteinuria was also increased in SHR-SP according to growth, whereas dietary iron restriction suppressed the increment of proteinuria. SHR-SP exhibited glomerulosclerosis and exacerbated renal interstitial fibrosis at 15 weeks old, indicating that SHR-SP developed hypertensive nephropathy in the adult stage; however, these changes were attenuated by dietary iron restriction. Gelatin zymography showed dietary iron restriction decreased both renal MMP-2 and MMP-9 activities in SHR-SP at 15 weeks old. Of interest, dietary iron restriction suppressed renal TGFβ-RI expression and Smad2 phosphorylation in SHR-SP. Furthermore, dietary iron restriction decreased renal fibrosis, renal MMP-2 and MMP-9 activities, renal TGFβ-RI expression, and Smad2 phosphorylation in rats with unilateral ureteral obstruction. Dietary iron restriction prevented the development of hypertension in weanling pre-hypertensive rats.

Entities:  

Keywords:  Hypertension; Hypertensive nephropathy; Iron restriction; Renal fibrosis

Mesh:

Substances:

Year:  2018        PMID: 29417224     DOI: 10.1007/s00380-018-1134-4

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  11 in total

Review 1.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 2.  Global burden of blood-pressure-related disease, 2001.

Authors:  Carlene M M Lawes; Stephen Vander Hoorn; Anthony Rodgers
Journal:  Lancet       Date:  2008-05-03       Impact factor: 79.321

Review 3.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

4.  Altered expression of intestinal duodenal cytochrome b and divalent metal transporter 1 might be associated with cardio-renal anemia syndrome.

Authors:  Yoshiro Naito; Hisashi Sawada; Makiko Oboshi; Keisuke Okuno; Seiki Yasumura; Yoshitaka Okuhara; Akiyo Eguchi; Koichi Nishimura; Yuko Soyama; Masanori Asakura; Masaharu Ishihara; Takeshi Tsujino; Tohru Masuyama
Journal:  Heart Vessels       Date:  2017-07-01       Impact factor: 2.037

5.  Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats.

Authors:  Yoshiro Naito; Shinichi Hirotani; Hisashi Sawada; Hirokuni Akahori; Takeshi Tsujino; Tohru Masuyama
Journal:  Hypertension       Date:  2011-01-24       Impact factor: 10.190

6.  Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats.

Authors:  Yoshiro Naito; Takeshi Tsujino; Yoshihiro Fujimori; Hisashi Sawada; Hirokuni Akahori; Shinichi Hirotani; Mitsumasa Ohyanagi; Tohru Masuyama
Journal:  J Hypertens       Date:  2011-04       Impact factor: 4.844

7.  Association between renal iron accumulation and renal interstitial fibrosis in a rat model of chronic kidney disease.

Authors:  Yoshiro Naito; Aya Fujii; Hisashi Sawada; Makiko Oboshi; Toshihiro Iwasaku; Yoshitaka Okuhara; Daisuke Morisawa; Akiyo Eguchi; Shinichi Hirotani; Tohru Masuyama
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

8.  Iron restriction inhibits renal injury in aldosterone/salt-induced hypertensive mice.

Authors:  Hisashi Sawada; Yoshiro Naito; Makiko Oboshi; Toshihiro Iwasaku; Yoshitaka Okuhara; Daisuke Morisawa; Akiyo Eguchi; Shinichi Hirotani; Tohru Masuyama
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

Review 9.  Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy.

Authors:  Robert L Chevalier; Michael S Forbes; Barbara A Thornhill
Journal:  Kidney Int       Date:  2009-04-01       Impact factor: 10.612

10.  Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats.

Authors:  Teresa M Camp; Lane M Smiley; Melvin R Hayden; Suresh C Tyagi
Journal:  J Hypertens       Date:  2003-09       Impact factor: 4.844

View more
  3 in total

1.  MiR-216a accelerates proliferation and fibrogenesis via targeting PTEN and SMAD7 in human cardiac fibroblasts.

Authors:  Jinsong Tao; Jingyi Wang; Chunyu Li; Weiwei Wang; Hao Yu; Jinhui Liu; Xiangqing Kong; Yan Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

2.  Catheter-Based Radiofrequency Renal Sympathetic Denervation Decreases Left Ventricular Hypertrophy in Hypertensive Dogs.

Authors:  Shan Tu; Zhi-Jie Shen; Xiao-Yan Wang; Li-Xiong Zeng; Zhi-Hui Zhang
Journal:  Mediators Inflamm       Date:  2021-04-24       Impact factor: 4.711

3.  Haploinsufficiency of Transferrin Receptor 1 Impairs Angiogenesis with Reduced Mitochondrial Complex I in Mice with Limb Ischemia.

Authors:  Keisuke Okuno; Yoshiro Naito; Seiki Yasumura; Hisashi Sawada; Masanori Asakura; Tohru Masuyama; Masaharu Ishihara
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.